TCS launches AI agent platform; aims to transform drug development

In August 2026, Tata Consultancy Services recently launched TCS ADD AgentHub, which is a role-based, enterprise-ready AI platform that is designed to enable pharmaceutical companies to deploy agentic AI across drug development at scale. The platform is designed to support clinical trials and pharmacovigilance while also helping in addressing the governance, oversight and auditability requirements of highly regulated pharmaceutical environments.

Pharmaceutical companies operate in highly regulated environments and face challenges related to trust, governance and scalability when deploying AI across functions. Growing data volumes, fragmented systems and increasing regulatory expectations across clinical development and pharmacovigilance have further added to the complexities of the entire R&D value chain. Against this backdrop, TCS said the platform would help to provide a structured framework to mitigate these challenges, thus allowing AI agents to operate with clear roles, defined oversight and built-in auditability.

Built on the TCS ADD framework, the platform is designed to deliver operational benefits across drug development and safety functions. Solutions powered by the platform have demonstrated up to 40% efficiency gains in clinical data management activities, up to 30% reduction in clinical study build effort through metadata-driven automation, and up to 30% cost savings in end-to-end safety case processing. AI-powered safety agents can also reduce quality control effort by up to 50%. TCS ADD AgentHub supports a human + AI operating model, in which AI agents are embedded into enterprise workflows while humans retain responsibility for governance and decision-making.

Impact on the AI Market

Pharmaceutical companies all over the world face growing complexity in applying AI across research and development, driven by increasing data volumes, fragmented systems and evolving regulatory requirements. TCS ADD AgentHub provides a framework in which AI agents operate with defined roles, oversight and built-in auditability. Pharma companies can now configure and deploy AI agents across clinical workflows with limited integration and implementation effort.

The platform also supports workflows across clinical development and pharmacovigilance, including ICSR intake, data entry, coding, review and literature analysis; study design, protocol digitization and clinical data review; SDTM transformation; and medical monitoring assistance. TCS said its catalogue of AI agents can be deployed progressively based on an organization’s requirements and technology landscape.

Impact on the Generative AI In Healthcare Market

The global generative AI in healthcare market size is valued at USD 2.64 billion in 2025 and is projected to grow from USD 3.57 billion in 2026 to approximately USD 48.23 billion by 2035, at a CAGR of 33.71% from 2026 to 2035.

According to Precedence Research, the global generative AI in the healthcare market is being driven by several factors, including growing collaboration among the key players, technological advancements, and growing research and development activities. Furthermore, it can be used for data anonymization, removing personally identifiable information while preserving statistical properties and ensuring patient privacy. The global generative AI in the healthcare market is being driven by several factors, including growing collaboration among the key players, technological advancements, and growing research and development activities.

Collaborative efforts between technology providers, healthcare institutions, and research organizations are further helping to drive the generative AI market in healthcare. These collaborations help to foster the exchange of knowledge, resources, and expertise, pushing the boundaries of generative AI applications in healthcare. Additionally, advancements in AI technologies, computational power, and data availability contribute to the growth and sophistication of generative AI solutions. Thus, this is expected to open opportunities for the growth of the market during the forecast period.

Impact on the Artificial Intelligence (AI) In Precision Medicine Market

The global artificial intelligence (AI) in precision medicine market size was accounted for USD 3.15 billion in 2025 and is anticipated to reach around USD 60.24 billion by 2035, growing at a CAGR of 34.33% from 2026 to 2035.

According to Precedence Research, the market is experiencing significant growth due to the increasing demand for personalized treatments. Moreover, the increasing prevalence of various life-threatening diseases and advancements in genomics and multi-omics technologies contribute to market expansion. Furthermore, the increasing accessibility to digital health-related data and research methodology for data analysis will create tremendous opportunities and development potential for the market in the near future.

The ever-increasing need and demand for tailored medications, the growing number of people living with various types of diseases such as respiratory illnesses and heart diseases, and rapidly increasing R&D spending globally, combined with the large number of companies that are progressively adopting collaborations and partnerships as key market strategies, are key factors driving the global market growth.

Expert Opinion

Debashis Ghosh, President, Life Sciences and Healthcare, TCS, said,

“TCS ADD AgentHub is a role-based, enterprise-ready, and trusted AI platform that will enable our customers to accelerate drug development using agentic AI at scale. It enables a shift from reactive to proactive, scalable, and audit-ready operations amidst an ever-changing regulatory environment. TCS’ strategy is to move towards autonomous enterprise functions where an AI agentic workforce operates alongside humans, driving innovation in drug development and improving patient safety.”